{"entity":{"type":"insider","cik":"0001914883","url":"/insider/0001914883","json_url":"/insider/0001914883.json","name":"Readnour Robin Shane","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":22,"n_filings":7,"first":"2022-03-31","last":"2026-08-19","span_basis":"filed_date"},"name_variants":[{"name":"Readnour Robin Shane","source":"filing","n_filings":7,"first_seen":"2022-03-31","last_seen":"2026-08-19"}],"transactions":[{"id":9298441,"accession":"0001193125-26-357225","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-357225","line_url":"/filing/0001193125-26-357225","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35402.0,"shares_display":"35,402","price_per_share":6.0082,"price_display":"6.01","price_state":"stated","total_value":212702.2964,"total_display":"212,702.30","total_whole":"212,702","shares_owned_after":633867.0,"shares_owned_after_display":"633,867","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-17","filed_date":"2026-08-19","scope":"insider","n_lines":2},{"id":2467890,"accession":"0000950170-24-135150","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-135150","line_url":"/filing/0000950170-24-135150","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":1.49295,"price_display":"1.49","price_state":"stated","total_value":14929.5,"total_display":"14,929.50","total_whole":"14,930","shares_owned_after":652573.0,"shares_owned_after_display":"652,573","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-10","scope":"insider","n_lines":2},{"id":2467881,"accession":"0000950170-24-135150","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-135150","line_url":"/filing/0000950170-24-135150","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30772.0,"shares_display":"30,772","price_per_share":1.4293389704926556,"price_display":"1.43","price_state":"stated","total_value":43983.6188,"total_display":"43,983.62","total_whole":"43,984","shares_owned_after":647573.0,"shares_owned_after_display":"647,573","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-09","filed_date":"2024-12-10","scope":"insider","n_lines":2},{"id":2467872,"accession":"0000950170-24-135150","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-135150","line_url":"/filing/0000950170-24-135150","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":19228.0,"shares_display":"19,228","price_per_share":1.4455422924901187,"price_display":"1.45","price_state":"stated","total_value":27794.8872,"total_display":"27,794.89","total_whole":"27,795","shares_owned_after":564999.0,"shares_owned_after_display":"564,999","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-06","filed_date":"2024-12-10","scope":"insider","n_lines":2},{"id":2243263,"accession":"0000950170-24-131660","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-131660","line_url":"/filing/0000950170-24-131660","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":1.4168,"price_display":"1.42","price_state":"stated","total_value":70840.0,"total_display":"70,840.00","total_whole":"70,840","shares_owned_after":552288.0,"shares_owned_after_display":"552,288","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-27","filed_date":"2024-11-27","scope":"insider","n_lines":2},{"id":2243257,"accession":"0000950170-24-131660","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-131660","line_url":"/filing/0000950170-24-131660","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":1.3938,"price_display":"1.39","price_state":"stated","total_value":34845.0,"total_display":"34,845.00","total_whole":"34,845","shares_owned_after":597573.0,"shares_owned_after_display":"597,573","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-26","filed_date":"2024-11-27","scope":"insider","n_lines":2},{"id":2243139,"accession":"0000950170-24-129830","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-129830","line_url":"/filing/0000950170-24-129830","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":1.1574,"price_display":"1.16","price_state":"stated","total_value":57870.0,"total_display":"57,870.00","total_whole":"57,870","shares_owned_after":585073.0,"shares_owned_after_display":"585,073","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-20","filed_date":"2024-11-21","scope":"insider","n_lines":2},{"id":2243132,"accession":"0000950170-24-129830","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-129830","line_url":"/filing/0000950170-24-129830","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":1.03505,"price_display":"1.04","price_state":"stated","total_value":155257.5,"total_display":"155,257.50","total_whole":"155,258","shares_owned_after":489788.0,"shares_owned_after_display":"489,788","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-19","filed_date":"2024-11-21","scope":"insider","n_lines":2},{"id":2382303,"accession":"0001209191-24-001770","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001770","line_url":"/filing/0001209191-24-001770","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1425.0,"shares_display":"1,425","price_per_share":21.91495438596491,"price_display":"21.91","price_state":"stated","total_value":31228.81,"total_display":"31,228.81","total_whole":"31,229","shares_owned_after":485073.0,"shares_owned_after_display":"485,073","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-12","filed_date":"2024-01-17","scope":"insider","n_lines":2},{"id":2888186,"accession":"0001209191-24-001537","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001537","line_url":"/filing/0001209191-24-001537","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3669.0,"shares_display":"3,669","price_per_share":21.925094031071136,"price_display":"21.93","price_state":"stated","total_value":80443.17,"total_display":"80,443.17","total_whole":"80,443","shares_owned_after":415494.0,"shares_owned_after_display":"415,494","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-10","filed_date":"2024-01-12","scope":"insider","n_lines":2},{"id":6502360,"accession":"0000899243-22-012991","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-22-012991","line_url":"/filing/0000899243-22-012991","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914883","owner_name":"Readnour Robin Shane","owner_display_name":"Readnour Robin Shane","owner_url":"/insider/0001914883","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":153334.0,"shares_display":"153,334","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2300010.0,"total_display":"2,300,010.00","total_whole":"2,300,010","shares_owned_after":487592.0,"shares_owned_after_display":"487,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-29","filed_date":"2022-03-31","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":22,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":16,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":22},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001880438","name":"AN2 Therapeutics, Inc.","url":"/issuer/0001880438","role":"Director","n_filings":7,"first_seen":"2022-03-31","last_seen":"2026-08-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001914883","retrieved_at":"2026-08-27T11:29:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}